References
Abrahamsson C, Duker G, Lundberg C, Carlsson L. (1993).
Electrophysiological and inotropic effects of H 234/09 (almokalant) in
vitro: a comparison with two other novel IK blocking drugs, UK-68,798
(dofetilide) and E-4031. Cardiovasc Res 27:861-867.
Alexander SP, Striessnig J, Kelly E, Marrion NV, Peters JA, Faccenda E,
… Davies JA. (2017). The concise guide to pharmacology 2017/18:
Voltage-gated ion channels. Br J Pharmacol, 174:S160-S194.
Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A,
… van Dijk JG. (2018). ESC Guidelines for the diagnosis and
management of syncope. Eur Heart J, 39:1883-1948.
Briganti A, Evangelista F, Centonze P, Rizzo A, Bentivegna F, Crovace A,
Staffieri F. (2018). A preliminary study evaluating cardiac output
measurement using Pressure Recording Analytical Method (PRAM) in
anaesthetized dogs. BMC Vet Res, 14:72.
Champéroux P, Viaud K, El Amrani AI, Fowler JS, Martel E, Le Guennec JY,
Richard S. (2005). Prediction of the risk of Torsade de Pointes using
the model of isolated canine Purkinje fibres. Br J Pharmacol,
144:376-385.
Champéroux P, Ouillé A, Martel E, Fowler JS, Maurin A, Jude S, …
Richard S. (2010). Interferences of the autonomic nervous system with
drug induced QT prolongation: a point to consider in non-clinical safety
studies. J Pharmacol Toxicol Methods, 61:251-263.
Champéroux P, Thireau J, Jude S, Laigot-Barbé C, Maurin A, Sola ML,
… Le Guennec JY. (2015). Dofetilide induced QT interval short
term variability and ventricular arrhythmias are dependent on high
frequency autonomic oscillations. Br J Pharmacol, 172:2878-2891.
Champéroux P, Le Guennec JY, Jude S, Laigot C, Maurin A, Sola ML,
… Thireau J. (2016). The high frequency relationship:
implications for torsadogenic hERG blockers. Br J Pharmacol,
173:601-612.
Champéroux P, Fesler P, Judé S, Richard S, Le Guennec JY, Thireau J.
(2018). High-frequency autonomic modulation: a new model for analysis of
autonomic cardiac control. Br J Pharmacol, 175:3131-3143.
Chiba K, Ishizaka T, Yoshimatsu Y, Mikamoto K, Maeda Y, Iguchi T,
… Mori K. (2020). Comprehensive analysis of cardiac function,
blood biomarkers and histopathology for milrinone-induced cardiotoxicity
in cynomolgus monkeys. J Pharmacol Toxicol Methods. 103:106870. doi:
10.1016/j.vascn.2020.106870. Epub 2020
Couderc JP (2012). The Telemetric and Holter ECG Warehouse (THEW): the
first three years of development and research. J Electrocardiol,
45:677-683.
Goldenberg I, Horr S, Moss AJ, Lopes CM, Barsheshet A, McNitt S,
… Zhang L. (2011). Risk for life-threatening cardiac events in
patients with genotype-confirmed long-QT syndrome and normal-range
corrected QT intervals. J Am Coll Cardiol, 57:51-59.
Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S,
… Davies JA. The IUPHAR/BPS Guide to PHARMACOLOGY in 2018:
updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.
Nucl Acids Res 2018; 46: D1091–D1106.
Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A,
Verducci JS, Brown AM. MICE models: superior to the HERG model in
predicting Torsade de Pointes. Sci Rep, 3:2100.
Kannankeril P, Roden DM, Darbar D. (2010). Drug-induced long QT
syndrome. Pharmacol Rev, 62:760-781.
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). NC3Rs
Reporting Guidelines Working Group. Animal research: reporting in vivo
experiments: the ARRIVE guidelines. Br J Pharmacol, 160: 1577–1579.
Kim JA, Lopes CM, Moss AJ, McNitt S, Barsheshet A, Robinson JL, …
Goldenberg I. (2010). Trigger-specific risk factors and response to
therapy in long QT syndrome type 2. Heart Rhythm, 7:1797-1805.
Kouchoukos NT, Sheppard LC, McDonald DA. (1970). Estimation of stroke
volume in the dog by a pulse contour method. Circ Res, 26:611-23.
Le Guennec JY, Thireau J, Ouillé A, Roussel J, Roy J, Richard S,
… Champéroux P. (2016). Inter-individual variability and modeling
of electrical activity: a possible new approach to explore cardiac
safety?. Sci Rep, 6:37948.
Lengyel C, Varró A, Tábori K, Papp JG, Baczkó I. (2007). Combined
pharmacological block of I(Kr) and I(Ks) increases short-term QT
interval variability and provokes torsades de pointes. Br J Pharmacol,
151:941-951.
Maltsev VA, Silverman N, Sabbah HN, Undrovinas AI. (2007). Chronic heart
failure slows late sodium current in human and canine ventricular
myocytes: implications for repolarization variability. Eur J Heart Fail,
9:219-227.
McGrath JC, Lilley E (2015). Implementing guidelines on reporting
research using animals (ARRIVE etc.): new requirements for publication
in BJP. Br J Pharmacol, 172: 3189–3193.
Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J,
… Choi S. (1991). The long QT syndrome. Prospective longitudinal
study of 328 families. Circulation. 84:1136-1144.
Näbauer M, Kääb S. (1998). Potassium channel down-regulation in heart
failure.
Cardiovasc Res, 37:324-334.
Nedergaard OA, Abrahamsen J. (1988). Effect of chlorpromazine on
sympathetic neuroeffector transmission in the rabbit isolated pulmonary
artery and aorta. Br J Pharmacol, 93:23-34.
Nourian Z, Mulvany MJ, Nielsen KB, Pickering DS, Kristensen T. (2008).
The antagonistic effect of antipsychotic drugs on a HEK293 cell line
stably expressing human alpha1A1-adrenoceptors. Eur J Pharmacol,
596:32-40.
O’Connell TD, Jensen BC, Baker AJ, Simpson PC. (2014). Cardiac
alpha1-adrenergic receptors: novel aspects of expression, signaling
mechanisms, physiologic function, and clinical importance. Pharmacol
Rev, 66:308-33.
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM,
Hendrix GH, … DeMets DL. (1991). Effect of oral milrinone on
mortality in severe chronic heart failure. The PROMISE Study Research
Group. N Engl J Med, 325:1468-1475.
Page A, Aktas MK, Soyata T, Zareba W, Couderc JP. (2015). ”QT clock” to
improve detection of QT prolongation in long QT syndrome patients. Heart
Rhythm, 13:190-198.
Park E, Gintant GA, Bi D, Kozeli D, Pettit SD, Pierson JB, …Valentin
JP. Can non-clinical repolarization assays predict the results of
clinical thorough QT studies? Results from a research consortium. Br J
Pharmacol, 175:606-617.
Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm
J, … Van Veldhuisen DJ. (2015). ESC Guidelines for the management of
patients with ventricular arrhythmias and the prevention of sudden
cardiac death: The Task Force for the Management of Patients with
Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of
the European Society of Cardiology (ESC). Eur Heart J, 36:2793-2867.
Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S,
… Hammond TG. (2003). Relationships between preclinical cardiac
electrophysiology, clinical QT interval prolongation and torsade de
pointes for a broad range of drugs: evidence for a provisional safety
margin in drug development. Cardiovasc Res 58:32-45.
Shimizu W, Antzelevitch C. (1999). Cellular basis for long QT,
transmural dispersion of repolarization, and torsade de pointes in the
long QT syndrome. J Electrocardiol, 32 Suppl:177-184.
Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C,
… Bloise R. (2001). Genotype-phenotype correlation in the long-QT
syndrome: gene-specific triggers for life-threatening arrhythmias.
Circulation, 103:89-95.
Sleight AJ, Koek W, Bigg DC. (1993). Binding of antipsychotic drugs at
alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the
alpha 1B-adrenoceptors. Eur J Pharmacol, 238:407-410.
Tande PM, Bjørnstad H, Yang T, Refsum H. (1990). Rate-dependent class
III antiarrhythmic action, negative chronotropy, and positive inotropy
of a novel Ik blocking drug, UK-68,798: potent in guinea pig but no
effect in rat myocardium. J Cardiovasc Pharmacol, 16:401-410.
Task Force of the European Society of Cardiology and the North American
Society of Pacing and Electrophysiology. (1996). Heart rate variability:
standards of measurement, physiological interpretation, and clinical
use. Circulation, 93:1043–1065.
Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, …
Karle CA. (2004). Inhibition of human ether-a-go-go-related gene
potassium channels by alpha 1-adrenoceptor antagonists prazosin,
doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol,
369:462-472.
Thomsen MB, Verduyn SC, Stengl M, Beekman JD, de Pater G, van Opstal J,
… Vos MA. (2004). Increased short-term variability of repolarization
predicts d-sotalol-induced torsades de pointes in dogs. Circulation,
110:2453-2459.
Viskin S, Fish R, Zeltser D, Belhassen B, Heller K, Brosh D, … Barron
HV. (2000). Arrhythmias in the congenital long QTsyndrome: how often is
torsade de pointes pause dependent? Heart, 83: 661–666.
Volders PGA, Stengl M, van Opstal JM, Gerlach U, Spätjens R, Beekman
JDM, … Vos MA. (2003). Probing the contribution of IKs to canine
ventricular repolarization: key role for beta-adrenergic receptor
stimulation. Circulation, 107:2753-2760.
Yang T, Chun YW, Stroud DM, Mosley JD, Knollmann BC, Hong C, Roden DM.
(2014). Screening for
acute IKr block is insufficient to detect torsades de pointes liability:
role of late sodium current. Circulation,130:224-234.
Yunomae K, Ichisaki S, Matsuo J, Nagayama S, Fukuzaki K, Nagata R, Kito
G. (2007). Effects of phosphodiesterase (PDE) inhibitors on human
ether-a-go-go related gene (hERG) channel activity. J Appl Toxicol,
27:78-85.
Zamir M, Kimmerly DS, Shoemaker JK. (2012). Cardiac mechanoreceptor
function implicated during premature ventricular contraction. Auton
Neurosci , 167:50-55.